论文部分内容阅读
2017年9月,FDA批准辉瑞公司的吉姆单抗/奥佐米星(gemtuzumab ozogamicin,Mylotarg)用于治疗新确诊的表达CD33抗原的急性髓系白血病(CD33阳性AML)成人患者。FDA还批准本品用于治疗2岁及以上的复发或对初始治疗无反应的CD33阳性AML患者。本品为靶向治疗药物,其通过将抗肿瘤药送至表达CD33抗原的AML细胞中,阻止癌细胞生长并导致细胞死亡。AML是一种快速发展的癌症,形成于骨髓,可导致血液中白细胞数量增加。美国国立卫生研究院的国家癌症
In September 2017, the FDA approved Pfizer’s gemtuzumab ozogamicin (Mylotarg) for the treatment of newly diagnosed adults with acute myeloid leukemia (CD33-positive AML) expressing the CD33 antigen. FDA also approved the use of this product in patients with CD33-positive AML who have relapsed 2 years and older or have not responded to initial treatment. This product is a targeted therapies that prevent the growth of cancer cells and cause cell death by delivering antineoplastic agents to AML cells that express the CD33 antigen. AML is a rapidly developing cancer that forms in the bone marrow and causes an increase in the number of white blood cells in the blood. National Institutes of Health National Cancer